Thousands of men with prostate cancer in England will be offered a more precise form of radiotherapy that cuts treatment time by up to 75 per cent, based on the results of a trial led by The Institute of Cancer Research (ICR), London and Royal Marsden NHS Foundation Trust. The therapy is known as SABR or SBRT.

A new UK-based study is shedding light on a quiet but consequential problem in cancer research: whether some people have less opportunity than others to participate in clinical trials.